Abstract

Background

Although vitamin D concentration is reportedly associated with the pathogenesis and pathology of systemic lupus erythematosus (SLE), benefits of vitamin D supplementation in SLE patients have not been elucidated, to our knowledge. We investigated the clinical impacts of vitamin D supplementation in SLE.

Methods

A cross-sectional analysis was performed using data from a lupus registry of nationwide institutions. We evaluated vitamin D supplementation status associated with disease-related Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) as a parameter of long-term disease activity control.
Results

Of the enrolled 870 patients (mean age: 45 years, mean disease duration: 153 months), 426 (49%) received vitamin D supplementation. Patients with vitamin D supplementation were younger (43.2 vs 47.5 years, \( P < 0.0001 \)), received higher doses of prednisolone (7.6 vs 6.8 mg/day, \( P = 0.002 \)), and showed higher estimated glomerular filtration rates (79.3 vs 75.3 mL/min/1.73m\(^2\), \( P = 0.02 \)) than those without supplementation. Disease-related SDI (0.73 ± 1.12 vs 0.73 ± 1.10, \( P = 0.75 \)), total SDI, and SLE Disease Activity Index (SLEDAI) did not significantly differ between patients receiving and not receiving vitamin D supplementation. Even after excluding 136 patients who were highly recommended vitamin D supplementation (with age \( \geq 75 \) years, history of bone fracture or avascular necrosis, denosumab use, and end-stage renal failure), disease-related SDI, total SDI, and SLEDAI did not significantly differ between the two groups.

Conclusions

Even with a possible Vitamin D deficiency and a high risk of bone fractures in SLE patients, only half of our cohort received its supplementation. The effect of vitamin D supplementation for disease activity control was not observed.

Introduction

Vitamin D deficiency plays a role in both the pathogenesis and pathology of systemic lupus erythematosus (SLE). SLE patients exhibit a higher prevalence of vitamin D deficiency [1, 2], and 1,25-dihydroxy vitamin D plays a preventive role in SLE incidence by regulating type I interferon and antibody production by inhibiting dendritic cell differentiation and T and B cell proliferation [3–5]. NK-cell immunity is as well critical for viral and immune mediated diseases and its dysregulation as a consequence of vitamin D deficiency could worsen disease activity in SLE also influence on disease activities by dysregulating NK-cell immunity [6–8]. Vitamin D deficiency also influences the microbiome patterns which are associated with autoimmune diseases such as SLE [9]. Vitamin D concentration shows an inverse correlation with anti-double-stranded DNA (anti-dsDNA) antibody titres [10] and disease activity [10–13] in SLE patients.

Pathology of SLE has been reported to be strongly associated with vitamin D deficiency; however, the positive effects of vitamin D supplementation on disease activity in SLE patients have not yet been elucidated, to our knowledge [14]. Clinical guidelines [15–18] have recommended vitamin D supplementation only for osteoporosis treatment in SLE patients [18]. Considering that glucocorticoids and other immunosuppressants have been reported to control disease activity enough in SLE patients, it is difficult to evaluate the relationship between vitamin D supplementation and short-term disease activity control in SLE patients [14]. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI) is used to assess disease- and treatment-related damage accumulation during the clinical course of SLE [19–21]. Using disease-related SDI as a marker for the accumulative consequences of long-term disease activity control in SLE patients [22], we evaluated the clinical impact of vitamin D supplementation on SLE patients. Since SDI since organ damage in SLE accumulates over a long period of time, with a reported change in
SDI of less than 1 in 10 years [23], we evaluated the outcome cross-sectionally for our cohort with a relatively long disease duration, averaging more than ten years.

The objective of this study was to describe vitamin D supplementation status in daily clinical practice and evaluate the relationship between vitamin D supplementation and disease-related damage accumulated as a result of disease activity in SLE patients.

Materials and methods

Database

Established in 2016, the lupus registry of nationwide institutions (LUNA) is a nationwide multicentre observational cohort database of SLE patients from 9 referral institutions in Japan. All patients were over 20 years of age and had scores of ≥4 according to the ACR classification criteria for SLE [24]. Baseline data obtained at registration included demographic information, date of disease onset, underlying comorbidities, smoking and drinking habits, medical history, reproductive history, and blood pressure. Laboratory data obtained at registration included results of complete blood count analysis, biochemical examination, urinalysis, complement level analysis, anti-dsDNA antibody titre analysis, and antiphospholipid antibody (lupus anticoagulant and anticardiolipin-β2-glycoprotein I complex antibodies) analysis. Disease activity and damage were evaluated using the SLE Disease Activity Index (SLEDAI) [24] and SDI [25], respectively. Data regarding current and previous treatments for SLE, such as glucocorticoid dosage and concomitant immunosuppressant use, and treatments for comorbidities including osteoporosis, such as calcium and vitamin D supplementation and bisphosphonate, denosumab, and teriparatide use, were also collected.

Patient selection

In the present study, all inpatients and outpatients registered in the LUNA registry up until August 2019 were enrolled. Vitamin D supplementation status was evaluated in all the registered patients except those who were currently pregnant or had malignancies.

For sensitivity analysis, patients who were highly recommended vitamin D supplementation were excluded using the following criteria: (1) age ≥75 years at SLE diagnosis (high prevalence of osteoporosis), (2) history of bone fracture or avascular necrosis (requiring vitamin D supplementation for secondary prevention of bone disease), (3) use of denosumab (requiring concomitant vitamin D supplementation), and (4) presence of end-stage renal failure (requiring vitamin D supplementation for chronic kidney disease-mineral and bone disorder). Patients with end-stage renal failure were defined as those with irreversible levels of estimated glomerular filtration rates (eGFRs) <15 mL/min/1.73m² or those requiring dialysis irrespective of the eGFR [26]. We have no data on past status or duration of vitamin D supplement. Therefore, we also performed additional analysis including patients only with duration ≥ 60 months to excluded those who might take vitamin D supplement only for short periods. Another analysis was performed excluding patients without prednisolone for dealing with possible effects of prednisolone use on vitamin D levels.

Outcome measures

The primary outcome measure in this study was disease-related SDI and the respective domains constituting total SDI. Disease-related SDI comprised SDI items (neuropsychiatric, renal, pulmonary, cardiovascular, peripheral vascular, gastrointestinal, and skin involvements, retinal change or optic atrophy, muscle atrophy/weakness, arthritis, osteomyelitis, premature gonadal failure, and malignancy), associated with SLE after excluding items mainly associated
with glucocorticoid-use-related adverse effects (avascular osteonecrosis, osteoporotic fractures, diabetes mellitus, and cataracts), as defined [27] and validated [28] by previous studies. Secondary outcome measures were total SDI and SLEDAI at registration.

**Statistical analysis**

First, we described vitamin D supplementation status and associated patients’ characteristics. We also described the prevalence of bone diseases and other concomitant treatments for osteoporosis in all the enrolled patients. Next, we compared outcomes between patients with and those without vitamin D supplementation. For sensitivity analysis, we excluded patients who were highly recommended vitamin D supplementation and then compared outcomes between patients with and those without vitamin D supplementation. Continuous variables were compared using the Mann-Whitney $U$ test or Welch’s $t$-test, depending on data distribution between the two groups. Categorical variables were compared using the chi-squared test or Fisher’s direct probability test, as appropriate. The odds ratios for one or more disease-related SDI items were calculated for the respective domains constituting total SDI and were compared between patients receiving and not receiving vitamin D supplementation. For outcome variables that were significant in the univariate analysis, multivariate logistic regression analysis was performed to adjust for age, sex and PSL dose as possible confounding factors.

Missing data were seen on disease durations and prednisolone (PSL) doses and were complemented by multivariate normal imputation using the least squares method.

Clinical characteristics are presented as mean ± standard deviation (SD) for continuous variables and patient number (%) for categorical variables. $P$ values < 0.05 were considered statistically significant. All statistical analyses were performed using the JMP statistical software package for Windows, version 12.2.0 (SAS Institute Inc., Cary, NC, USA).

**Ethics approval and consent**

This study was conducted according to the Declaration of Helsinki and the ethical guidelines for epidemiologic research in Japan. The study protocol was approved by the ethics committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (authorisation number: Ken1909-025). All patients provided written informed consent to participate in the registry and gave permission to have their data published.

**Results**

**Patient characteristics**

Of the 929 patients registered in the LUNA study, 17 were excluded owing to a lack of data, 3 were excluded owing to current pregnancies, and 39 were excluded owing to current malignancies. In the 870 enrolled patients with a mean ± SD age of 45 ± 14 years and a mean disease duration of 153 ±121 months, the mean SLEDAI score was 5.3 ± 4.8 and the mean total SDI score was 1.1 ± 1.5. The mean PSL dose at registration was 7.2 ± 6.5 mg/day, and the mean previous maximum PSL dose was 40 ± 21 mg/day. Hydroxychloroquine was administered to 225 (26%) patients. With respect to immunosuppressants, azathioprine was administered to 99 (11%) patients, mycophenolate mofetil was administered to 112 (13%) patients, and tacrolimus was administered to 296 (34%) patients.

**Vitamin D supplementation and osteoporosis treatment**

Of the 870 enrolled patients, 426 (49%) received vitamin D supplementation. Characteristics of patients receiving (n = 426) and not receiving (n = 444) vitamin D supplementation are...
Patients receiving vitamin D supplementation were younger (43.2 ± 14.6 vs 47.5 ± 14.5 years, \(P < 0.0001\)), had higher PSL doses (7.6 ± 6.2 vs 6.8 ± 6.7 mg/day, \(P = 0.002\)), showed higher eGFRs (79.3 ± 26.1 vs 75.3 ± 24.7 mL/min/1.73 m\(^2\), \(P = 0.02\)), and concomitantly used bisphosphonate less frequently (38% vs 46%, \(P = 0.02\)) than those not receiving vitamin D supplementation.

In this study, 95 (11%) patients experienced fractures or avascular necrosis and 657 (76%) received at least one treatment for osteoporosis; 426 (49%) received vitamin D supplementation, 36 (4%) received calcium supplementation, 369 (42%) received bisphosphonates, 14 (2%) received teriparatide, 16 (2%) received denosumab, and 4 (0.005%) received selective oestrogen receptor modulators. Of the 426 patients with vitamin D supplementation, 49 (12%) experienced fractures or avascular necrosis. Patients with a history of fracture or avascular necrosis were older (45 ± 15 vs 51 ± 15 years, \(P < 0.0001\)) and received denosumab (7% vs 1%, \(P < 0.0001\)) or teriparatide (7% vs 1%, \(P < 0.0001\)) more frequently than those without a history of fracture or avascular necrosis. There were no differences in vitamin D supplementation (52% vs 49%, \(P = 0.59\)) and bisphosphonate prescription (40% vs 43%, \(P = 0.61\)) between patients with and without a history of fracture or avascular necrosis (S1 Table).

### Outcomes related to vitamin D supplementation

No significant differences in disease-related SDI and the respective domains of total SDI were observed between patients receiving and not receiving vitamin D supplementation (disease-related SDI: 0.73 ± 1.12 vs 0.73 ± 1.10, \(P = 0.75\)) (S2 Table). For sensitivity analysis, 136 patients with age ≥ 75 years, a history of bone fracture or avascular necrosis, and end-stage renal disease were excluded. Characteristics of the included patients receiving (n = 358) and not receiving (n = 376) vitamin D supplementation are shown in Table 1. Even in the included patients, no significant differences in disease-related SDI and the respective domains of total SDI were observed between patients receiving and not receiving vitamin D supplementation (disease-related SDI: 0.55 ± 0.94 vs 0.62 ± 0.95, \(P = 0.19\)) (S2 Table). Odds ratios for SDI and the respective domains of total SDI between the total enrolled and included patients receiving and not receiving vitamin D supplementation are shown in Fig 1. A significant association between diabetes and vitamin D supplementation was found in the sensitivity analysis (odds ratio: 0.46, 95% confidence interval [CI]: 0.22–0.99), but no significant association between the two was found after adjusting for confounding factors (age, sex, and current PSL dose) in the logistic regression analysis (odds ratio: 0.65, 95% CI: 0.28–1.40). Similarly, no significant differences

| Characteristics | Primary analysis (n = 870) | Sensitivity analysis (n = 731) |
|-----------------|--------------------------|-------------------------------|
|                 | Vit. D (+) (n = 426) | Vit. D (-) (n = 444) | \(P\) value | Vit. D (+) (n = 358) | Vit. D (-) (n = 376) | \(P\) value |
| Age, years      | 43.2 ± 14.6              | 47.5 ± 14.5                  | <0.0001     | 41.0 ± 13.1              | 46.1 ± 13.3                  | <0.0001     |
| Disease duration, months | 149 ± 116          | 157 ± 126                  | 0.33        | 136 ± 108              | 149 ± 125                  | 0.14        |
| Number of female patients, n (%) | 385 (90)          | 385 (86)                  | 0.09        | 329 (92)               | 333 (89)                  | 0.13        |
| Mean SLEDAI, n (%) | 5.5 ± 5.1             | 5.2 ± 4.5                  | 0.62        | 5.5 ± 4.9              | 5.2 ± 4.5                  | 0.40        |
| Mean eGFR, mL/min/1.73 m\(^2\) | 79.3 ± 26.1         | 75.3 ± 24.7               | 0.02        | 81.0 ± 25.5           | 77.1 ± 23.9               | 0.03        |
| PSL dose at registration, mg/day | 7.6 ± 6.2          | 6.8 ± 6.7                | 0.002       | 7.8 ± 5.8              | 6.9 ± 7.1                 | 0.0006      |
| Max. PSL dose after diagnosis, mg/day | 40.9 ± 16.3         | 38.5 ± 18.8          | 0.05        | 40.7 ± 16.0           | 37.6 ± 18.8               | 0.02        |
| Bisphosphonate use, n (%) | 163 (38)           | 206 (46)                  | 0.02        | 139 (39)              | 176 (47)                  | 0.03        |

Vit., vitamin; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; eGFR, estimated glomerular filtration rate; PSL, prednisolone; max., maximum.

https://doi.org/10.1371/journal.pone.0270569.t001
in disease-related SDI and the respective domains of total SDI were observed between patients receiving and not receiving vitamin D supplementation in patients with disease duration ≥ 60 months (disease-related SDI: 0.61 ± 1.02 vs 0.70 ± 1.07, P = 0.33) or patients with prednisolone (disease-related SDI: 0.72 ± 1.13 vs 0.77 ± 1.13, P = 0.51).

ORs for SDI and the respective domains of total SDI (scores > 0) between the total enrolled and included patients receiving and not receiving vitamin D supplementation are compared. Closed circles represent the ORs, and bars represent the 95% CIs. GC, glucocorticoid; OR, odds ratio; SDI, SLICC/ACR Damage Index.

In both the total enrolled and included patients, no significant differences in SLEDAI scores were found between patients receiving and not receiving vitamin D supplementation (total enrolled patients: 5.5 ± 5.1 vs 5.2 ± 4.5, P = 0.62; included patients: 5.5 ± 4.9 vs 5.2 ± 4.5, P = 0.40).

Discussion

In the present study, we described vitamin D supplementation status and evaluated the relationship between vitamin D supplementation and disease-related SDI scores associated with damage accumulation and disease activity in SLE patients. Approximately half of the patients received vitamin D supplementation, which is comparable to other observational study in Japan [29], and most of those had no history of fracture or avascular necrosis. Disease-related SDI did not statistically differ between patients receiving and not receiving vitamin D supplementation.

The clinical effects of vitamin D supplementation on disease activity control may be quite limited in SLE patients. Previous studies have reported no clinically significant effects of vitamin D supplementation on disease activity despite favourable immunological changes in SLE patients [30–33]. Only one randomised controlled trial reported the efficacy of vitamin D supplementation compared to placebo use in juvenile SLE patients [34]. However, in this study, immunosuppressive treatment in itself may have been insufficient because patients receiving vitamin D supplementation showed no improvement in SLEDAI scores. Because no significant clinical effects of vitamin D supplementation were observed on short-term disease activity control using sufficient immunosuppressive treatments, we evaluated disease-related SDI as a marker for long-term disease activity control and damage accumulation in SLE patients. However, no statistical association was observed between vitamin D supplementation and disease-related SDI. Therefore, we cannot conclude that there is enough evidence of effect of vitamin D supplementation on SLE, at least at the dosage indicated and prescribed in daily practice for osteoporosis, though the effect at higher dosages was not examined in this observational study.

Vitamin D supplementation should be considered for bone mineral metabolism despite its efficacy in disease activity control being unclear. In our study, vitamin D supplementation was prescribed frequently for younger patients with higher dose of PSL and fewer concomitant uses of bisphosphonates. A recent meta-analysis reported that higher-dose vitamin D supplementation could reduce fracture risk by 15%–29% [35]. SLE patients are at a high risk of osteoporosis and bone fractures [36], even if they have normal bone mineral density values [37]. Bone diseases in SLE patients are considered to be exclusively associated with damage caused by glucocorticoid use [19, 27, 28], and the ACR guidelines have recommended vitamin D supplementation for glucocorticoid-induced osteoporosis regardless of fracture risk [38]. In the present study, approximately half of the patients received vitamin D supplementation, which corresponds with data reported by several previous cohort studies [39–41]. Vitamin D supplementation in SLE patients has been considered to be safe and well tolerated, with reports of only mild or infrequent hypercalcaemia in previous studies [14, 42], and can be used for
young women considering pregnancy for whom bisphosphonates were contraindicated. Vitamin D supplementation should be considered more proactively in all SLE patients, especially in young women without use of bisphosphonate.

This study had several limitations. First, we could not evaluate the dosing periods for vitamin D supplementation because of the cross-sectional design of the study. This may have led to an underestimation of the effects of vitamin D supplementation in SLE patients. However,

|                          | Primary analysis (n = 870) | Sensitivity analysis (n = 731) |
|--------------------------|---------------------------|-------------------------------|
| Total SDI                | OR 0                      | OR 0                          |
| Disease-related SDI      | OR 1.0                    | OR 1.0                        |
| GC-use-related SDI       | OR 0.65                   | OR 0.55                       |
| Ocular                   | OR 0.21                   | OR 0.55                       |
| Neuropsychiatric         | OR 0.55                   | OR 0.30                       |
| Renal                    | OR 0.44                   | OR 0.07                       |
| Pulmonary                | OR 0.27                   | OR 0.98                       |
| Cardiovascular           | OR 0.54                   | OR 0.74                       |
| Peripheral vascular      | OR 0.16                   | OR 0.06                       |
| Gastrointestinal         | OR 0.61                   | OR 0.26                       |
| Musculoskeletal          | OR 0.16                   | OR 0.15                       |
| Skin                     | OR 0.92                   | OR 0.91                       |
| Gonadal failure          | OR 0.64                   | OR 0.65                       |
| Diabetes                 | OR 0.29                   | OR 0.04                       |

Fig 1. ORs for SDI between patients receiving and not receiving vitamin D supplementation.

https://doi.org/10.1371/journal.pone.0270569.g001
medications for osteoporosis are generally administered long-term to prevent fractures rather than used for short periods of time in the acute phase. In practice, a retrospective study on prescriptions for osteoporosis in Japan reported a prescription continuation rate of more than 60% throughout the entire 18–24-month observation period [43]. Therefore, we may assume that the dosing periods in our study are long enough to evaluate. Second, there were no available data on vitamin D levels, calcium, phosphorus concentrations, and anti-phospholipids antibodies, which could have helped in examining the optimum dose for vitamin D supplementation. Insufficient doses of vitamin D supplementation and its sample size may also have led to an underestimation of its effects in SLE patients. Data on adherence was not collected in this study. However, it has been reported that drug adherence is better than 90% in SLE, even higher without harmful side effects [44]. So, the impact of adherence on the results may be relatively small. Also, our results might be less susceptible to vitamin D from other sources because supplement use of vitamin D and Vitamin D fortification of foods are uncommon in Japan [45]. Overall, despite these limitations, our large population study showed, if any, a limited impact of vitamin D supplementation on disease activity control in SLE patients in daily clinical practice.

Conclusion

Even with a possible Vitamin D deficiency and a high risk of bone fractures in SLE patients, only half of our cohort received its supplementation. The effect of vitamin D supplementation for disease activity control was not observed.

Supporting information

S1 Table. Comparison of osteoporosis treatment status between patients with and without a history of fracture or avascular necrosis.

S2 Table. Comparison of SDI scores and the respective domains of total SDI.

Acknowledgments

We express our gratitude to Tomomi Maruyama for her substantial assistance in data management. We also thank the members of the Division of Rheumatology, Department of Medicine, Showa University School of Medicine, for their contribution to this study.

Author Contributions

Conceptualization: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Data curation: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.
Formal analysis: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Investigation: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Methodology: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Project administration: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Resources: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Software: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Supervision: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Validation: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Visualization: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Writing – original draft: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro
Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

Writing – review & editing: Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada.

References

1. Kamen DL. Vitamin D in lupus—new kid on the block?. Bull NYU Hosp Jt Dis 2010; 68: 218–222. PMID: 20969555

2. Attar SM, Siddiqui AM. Vitamin d deficiency in patients with systemic lupus erythematosus. Oman Med J 2013; 28: 42–47. https://doi.org/10.5001/omj.2013.10 PMID: 23386945

3. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405–2411. https://doi.org/10.4049/jimmunol.164.5.2405 PMID: 10679076

4. van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO. 1alpha,25-dihydroxy vitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 2004; 23: 233–239. https://doi.org/10.1016/j.jaut.2004.06.004 PMID: 15501394

5. Lin SJ, Kuo ML, Hsiao HS, Lee PT, Chen JY, Huang JL. Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosus-regulation with interleukin-15. PLoS One 2017; 12: e0186223. https://doi.org/10.1371/journal.pone.0186223 PMID: 29023581

6. Ye Z, Ma N, Zhao L, Jiang ZY, et al. Differential expression of natural killer activating and inhibitory receptors in patients with newly diagnosed systemic lupus erythematosus. Int J Rheum Dis 2016; 19: 613–621. https://doi.org/10.1111/1756-185X.12289 PMID: 24617960

7. Lin SJ, Kuo ML, Hsiao HS, Lee PT, Chen JY, Huang JL. Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosis-regulation with interleukin-15. PLoS One 2017; 12: e0186223. https://doi.org/10.1371/journal.pone.0186223 PMID: 29023581

8. Murdaca G, Gerosa A, Paladin F, et al. Vitamin D and Microbiota: Is There a Link with Allergies?. Int J Mol Sci 2021; 22: 4288. https://doi.org/10.3390/ijms22084288 PMID: 33924232

9. Mok CC, Birmingham DJ, Leung HW, Hebert LA, Song H, Rovin BH. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus 2012; 21: 36–42. https://doi.org/10.1177/0961203311422094 PMID: 21993384

10. Amital H, Szekanecz Z, Szucs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Ann Rheum Dis 2010; 69: 1155–1157. https://doi.org/10.1136/ard.2009.120329 PMID: 20439290

11. Mok CC, Birmingham DJ, Leung HW, Hebert LA, Song H, Rovin BH. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology (Oxford) 2012; 51: 644–652. https://doi.org/10.1093/rheumatology/ker212 PMID: 22179424

12. Yap KS, Northcott M, Hoi AB, Morand EF, Nikpour M. Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Sci Med 2015; 2: e000064. https://doi.org/10.1136/lupus-2014-000064 PMID: 25893108

13. Hassanaliou T, Khalili L, Ghavamzadeh S, Shokri A, Payahoo L, Bishak YK. Role of vitamin D deficiency in systemic lupus erythematosus incidence and aggravation. Auto Immun Highlights 2017; 9: 1. https://doi.org/10.1007/s13317-017-0101-x PMID: 29280019

14. Fanourakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 736–745. https://doi.org/10.1136/annrheumdis-2019-215089 PMID: 30926722

15. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797–808.
17. Pons-Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). *Ann Rheum Dis* 2018; 77: 1549–1557. https://doi.org/10.1136/annrheumdis-2018-213512 PMID: 30045853

18. Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatology (Oxford)* 2018; 57: e1–e45.

19. Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. *J Rheumatol* 2003; 30: 1955–1959. PMID: 12966597

20. Urowitz MB, Gladman DD, Ibañez D, et al. Impact of disease activity on organ damage progression in systemic lupus erythematosus: University of Toronto Lupus Clinic *J Rheumatol* 2020; https://doi.org/10.3899/jrheum.190259 PMID: 32238510

21. Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, et al. The number of flares patients experience on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. *Ann Rheum Dis* 2015; 74: 1019–1023. https://doi.org/10.1136/annrheumdis-2013-204620 PMID: 24525909

22. Mak A, Cheung MW, Chiew HJ, Liu Y, Ho RC. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. *Semin Arthritis Rheum* 2012; 41: 830–839. https://doi.org/10.1016/j.semarthritis.2011.11.002 PMID: 22257558

23. Taraborelli M, Cavazzana I, Martinazzi N, et al. Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. Lupus 2017; 26: 1197–1204. https://doi.org/10.1177/0961203317693096 PMID: 28420047

24. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 1992; 35: 630–640. https://doi.org/10.1002/art.1780350606 PMID: 15995220

25. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum* 1996; 39: 363–369. https://doi.org/10.1002/art.1780390303 PMID: 8607884

26. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011; 80: 17–28. https://doi.org/10.1038/ki.2010.483 PMID: 21150873

27. Ruiz-Arzuza I, Ugarte A, Cabezás-Rodríguez I, Medina JA, Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. *Rheumatology (Oxford)* 2014; 53: 1470–1476. https://doi.org/10.1093/rheumatology/keu148 PMID: 24681836

28. Apostolopoulou D, Kandane-Rathnayake R, Raghunath S, Hoi A, Nikpour M, Morand EF. Independent association of glucocorticoids with damage accrual in SLE. *Lupus Sci Med* 2016; 3: e000157. https://doi.org/10.1136/lupus-2016-000157 PMID: 27933196

29. Sato H, Kondo N, Wakamatsu A, et al. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systemic lupus erythematosus: a single-center retrospective study performed in Japan. *Rheumatol Int* 2019; 39: 1803–1810. https://doi.org/10.1007/s00296-019-04407-4 PMID: 31385078

30. Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide MV, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. *Arthritis Care Res (Hoboken)* 2010; 62: 1160–1165.

31. Terrier B, Derian N, Schoindre Y, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. *Arthritis Res Ther* 2012; 14: R221. https://doi.org/10.1186/ar4060 PMID: 23075451

32. Marinho A, Carvalho C, Boleixa D, et al. Vitamin D supplementation effects on FoxP3 expression in T cells and FoxP3+/IL-17A ratio and clinical course in systemic lupus erythematosus patients: a study in a Portuguese cohort. *Immunol Res.* 2017; 65: 197–206. https://doi.org/10.1007/s12026-016-8829-3 PMID: 27423437

33. Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. *Arthritis Rheum* 2013; 65: 1865–1871. https://doi.org/10.1002/art.37953 PMID: 23553077

34. Lima GL, Paupitz J, Alkawa NE, Takayama L, Bonfa E, Pereira RM. Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis Care Res (Hoboken)* 2016; 68: 91–98. https://doi.org/10.1002acr.22621 PMID: 25988278
35. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D supplementation. *Osteoporos Int* 2010; 21: 1121–1132. https://doi.org/10.1007/s00198-009-1119-3 PMID: 19957164

36. Rhew EY, Lee C, Eksarko P, et al. Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus. *J Rheumatol* 2008; 35: 230–236. PMID: 18203323

37. Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. *Osteoporos Int* 2009; 20: 427–433. https://doi.org/10.1007/s00198-008-0676-1 PMID: 18600287

38. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Arthritis Rheumatol* 2017; 69: 1521–1537. https://doi.org/10.1002/art.40137 PMID: 28585373

39. Schmajuk G, Yelin E, Chakravarty E, Nelson LM, Panopolis P, Yazdany J. Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. *Arthritis Care & Research* 2010; 62: 993–1001.

40. Almehed K, Forsblad d’Elia H, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patients-extended report. *Rheumatology (Oxford)* 2007; 46: 1185–1190. https://doi.org/10.1093/rheumatology/kem105 PMID: 17500075

41. Lee C, Almagor O, Dunlop DD, Manzi S, Spies S, Ramsey-Goldman R. Self-reported fractures and associated factors in women with systemic lupus erythematosus. *J Rheumatol* 2007; 34: 2018–2023. PMID: 17787041

42. Aranow C, Kamen DL, Dall’Era M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. *Arthritis Rheumatol* 2015; 67: 1848–1817. https://doi.org/10.1002/art.39108 PMID: 25777546

43. Fujiwara S, Miyauchi A, Hamaya E, et al. Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review. *Arch Osteoporos* 2018; 13: 34. https://doi.org/10.1007/s11657-018-0443-7 PMID: 29564555

44. Hardy C, Gladman DD, Su J, Rozenbojm N, Urowitz MB. Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. *Rheumatol Int* 2021; 41: 1457–1464. https://doi.org/10.1007/s00296-021-04898-0 PMID: 34089358

45. Asakura K, Etoh N, Imamura H, et al. Vitamin D Status in Japanese Adults: Relationship of Serum 25-Hydroxyvitamin D with Simultaneously Measured Dietary Vitamin D Intake and Ultraviolet Ray Exposure. *Nutrients* 2020; 12: 743. https://doi.org/10.3390/nu12030743 PMID: 32168939